Biomarker Identifies Septic Patients at Higher Risk for Mortality
|
By LabMedica International staff writers Posted on 28 Jan 2020 |
|
Image: Blood smear of patient with intracellular cocci in pairs inside a white blood cell, possibly indicating sepsis. Oncostatin-M is a biomarker for sepsis risk (Photo courtesy of Dr. Wim van der Meer).
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion.
Oncostatin-M (OSM) is a pleiotropic cytokine of the interleukin-6 (IL-6) family. OSM secretion has been associated with the modulation of multiple inflammatory diseases, including rheumatoid arthritis, asthma, inflammatory bowel disease, osteoarthritis, hepatic cellular carcinoma and bacterial pneumonia. However, the role of OSM in sepsis has remained unclear.
Laboratory scientists at the Chongqing Medical University (Chongqing, China) enrolled 49 patients with sepsis at the Second Affiliated Hospital of the university intensive care unit (ICU) between October 2017 and December 2018 and analyzed serum OSM levels on their day of admission. The effects of OSM on polymicrobial sepsis induced by cecal ligation and puncture (CLP) were assessed.
The team reported that results of the study showed that on day 1 of ICU admission, septic patients had higher serum OSM levels compared with ICU patient controls and healthy volunteers. Further, they found that a high serum OSM level at ICU admission was independently predictive of 28-day mortality in septic patients, as was SOFA score. They reported that the area under the curve (AUC) of OSM for predicting 28-day mortality in septic patients was 0.80 on day of ICU admission which was significantly higher than that of SOFA score (AUC, 0.730) and procalcitonin (AUC, 0.65). The findings were supported in a mouse model. In CLP-induced polymicrobial sepsis, anti-OSM antibody decreased tissue inflammation and injury, and thus improved survival, while local and systemic bacterial dissemination was almost constant.
The authors concluded that their pilot study found a significant elevation in the serum OSM levels in the patients with sepsis, and OSM levels correlated with disease severity of sepsis. Moreover, the serum OSM level on day of ICU admission was related to 28-day mortality in septic patients. These results suggest that OSM measurement may represent a new biomarker for identification of a group of septic patients presenting with higher risk of mortality. The study was published on January 13, 2020 in the Journal of Infectious Diseases.
Related Links:
Chongqing Medical University
Oncostatin-M (OSM) is a pleiotropic cytokine of the interleukin-6 (IL-6) family. OSM secretion has been associated with the modulation of multiple inflammatory diseases, including rheumatoid arthritis, asthma, inflammatory bowel disease, osteoarthritis, hepatic cellular carcinoma and bacterial pneumonia. However, the role of OSM in sepsis has remained unclear.
Laboratory scientists at the Chongqing Medical University (Chongqing, China) enrolled 49 patients with sepsis at the Second Affiliated Hospital of the university intensive care unit (ICU) between October 2017 and December 2018 and analyzed serum OSM levels on their day of admission. The effects of OSM on polymicrobial sepsis induced by cecal ligation and puncture (CLP) were assessed.
The team reported that results of the study showed that on day 1 of ICU admission, septic patients had higher serum OSM levels compared with ICU patient controls and healthy volunteers. Further, they found that a high serum OSM level at ICU admission was independently predictive of 28-day mortality in septic patients, as was SOFA score. They reported that the area under the curve (AUC) of OSM for predicting 28-day mortality in septic patients was 0.80 on day of ICU admission which was significantly higher than that of SOFA score (AUC, 0.730) and procalcitonin (AUC, 0.65). The findings were supported in a mouse model. In CLP-induced polymicrobial sepsis, anti-OSM antibody decreased tissue inflammation and injury, and thus improved survival, while local and systemic bacterial dissemination was almost constant.
The authors concluded that their pilot study found a significant elevation in the serum OSM levels in the patients with sepsis, and OSM levels correlated with disease severity of sepsis. Moreover, the serum OSM level on day of ICU admission was related to 28-day mortality in septic patients. These results suggest that OSM measurement may represent a new biomarker for identification of a group of septic patients presenting with higher risk of mortality. The study was published on January 13, 2020 in the Journal of Infectious Diseases.
Related Links:
Chongqing Medical University
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
- Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Microbiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
